Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Sihuan Pharmaceutical Holdings Group Ltd. has announced that its subsidiary, Honghe Pharmaceutical, received approval from China’s National Medical Products Administration for their Ticagrelor Orodispersible Tablet, a novel antithrombotic medication. This first domestic product approval marks a significant addition to the Group’s cardiovascular drug portfolio and is expected to positively impact its operating performance in a market exceeding RMB 10 billion in 2023.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.